Cellectis Unveils Clinical Priorities for 2026
Biotechnology company Cellectis has outlined its strategic focuses for the current year, centered on advancing its allogeneic immunotherapy clinical trials. The company, listed on Euronext Growth and Nasdaq, plans to publish interim data for its pivotal trial in acute lymphoblastic leukemia.
Key Developments in Pivotal Clinical Trial
According to the press release, Cellectis aims to finalize the first interim analysis of its phase 2 BALLI-01 clinical trial in the fourth quarter of 2026. This pivotal trial, initiated in October 2025, investigates lasmé-cel, a treatment for patients with relapsed or refractory B-type acute lymphoblastic leukemia. The analysis will cover 40 patients, the company indicates. The group notes that this step is based on phase 1 data deemed encouraging, presented at a dedicated research and development day. André Choulika, CEO, emphasized that the year 2025 marked a turning point with the transition to advanced clinical stage in the field of allogeneic CAR-T.
Further Developments in Phase 1 Trials
As per the press release, Cellectis also plans to present the complete phase 1 data of the NATHALI-01 trial in 2026. This trial assesses éti-cel, a dual CAR-T-cell candidate, in the treatment of relapsed or refractory non-Hodgkin lymphoma. Preliminary phase 1 data had been shared at the annual meeting of the American Society of Hematology in December 2025. The group indicates it is focusing on maximizing the clinical impact of this therapeutic candidate. The company has internalized production capabilities, allowing it to control the entire value chain of cell and gene therapy.
Strategic Partnerships and Industry Engagement
According to the company, the year 2026 will be marked by leveraging the momentum of its strategic partnership with AstraZeneca. The press release also mentions collaborations with Servier, Allogene, and Iovance, without further details. The management team will participate in the 44th annual J.P. Morgan Healthcare Conference in San Francisco from January 12 to 15, 2026, with meetings scheduled with investors. Cellectis, headquartered in Paris, also has facilities in New York and Raleigh in the United States. The company is listed on the Euronext Growth market under the ticker ALCLS and on the Nasdaq Global Market under the ticker CLLS.
